| Delmar Kent Layton, MD | |
|
2050 W Southern Ave, Apache Junction, AZ 85120-7305 | |
| (602) 839-6968 | |
| (602) 839-4144 |
| Full Name | Delmar Kent Layton |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 2050 W Southern Ave, Apache Junction, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184687121 | NPI | - | NPPES |
| Entity Name | Emergency Professional Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518984210 PECOS PAC ID: 6901707272 Enrollment ID: O20040119000693 |
News Archive
The Alpha-1 Foundation announced today that it has awarded two research grants to investigators whose research will contribute to our understanding of the causes and mechanisms that give rise to lung disease.
On February 2 from 6pm to 8pm, the Emerging Infectious Diseases & Microbiology Discussion Group of the New York Academy of Sciences presents Dual Use Research: H5N1 Influenza Virus and Beyond, a discussion between scientists, publishers, and legal experts that will explore the myriad issues surrounding the impending publication of these two studies and measures that will need to be undertaken to ensure the security of future such research.
Researchers at Umeå University can now show that cells that grow forever get this capacity through gradual changes in the expression of genes that govern the repair of DNA damage and regulate growth and cell death. The research also shows that activation of the enzyme complex telomerase, which is necessary for unlimited growth, occurs late in this process.
Spectros Corporation announces the successful launch of OnCall wireless remote access for viewing real-time patient results on T-Stat white light tissue oximeters.
ProtAffin AG, a biotechnology company developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures, today announced it has signed a manufacturing contract with CMC Biologics' Danish operations, located in Copenhagen, Denmark for manufacture of its lead product PA401 for the treatment of chronic obstructive pulmonary disease (COPD). The contract will cover manufacture and supply of PA401 for preclinical development and early clinical development in COPD and related respiratory indications.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Delmar Kent Layton, MD Po Box 64568, Phoenix, AZ 85082-4568 Ph: (602) 839-6968 | Delmar Kent Layton, MD 2050 W Southern Ave, Apache Junction, AZ 85120-7305 Ph: (602) 839-6968 |
News Archive
The Alpha-1 Foundation announced today that it has awarded two research grants to investigators whose research will contribute to our understanding of the causes and mechanisms that give rise to lung disease.
On February 2 from 6pm to 8pm, the Emerging Infectious Diseases & Microbiology Discussion Group of the New York Academy of Sciences presents Dual Use Research: H5N1 Influenza Virus and Beyond, a discussion between scientists, publishers, and legal experts that will explore the myriad issues surrounding the impending publication of these two studies and measures that will need to be undertaken to ensure the security of future such research.
Researchers at Umeå University can now show that cells that grow forever get this capacity through gradual changes in the expression of genes that govern the repair of DNA damage and regulate growth and cell death. The research also shows that activation of the enzyme complex telomerase, which is necessary for unlimited growth, occurs late in this process.
Spectros Corporation announces the successful launch of OnCall wireless remote access for viewing real-time patient results on T-Stat white light tissue oximeters.
ProtAffin AG, a biotechnology company developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures, today announced it has signed a manufacturing contract with CMC Biologics' Danish operations, located in Copenhagen, Denmark for manufacture of its lead product PA401 for the treatment of chronic obstructive pulmonary disease (COPD). The contract will cover manufacture and supply of PA401 for preclinical development and early clinical development in COPD and related respiratory indications.
› Verified 4 days ago